Cagrilintide vs semaglutide: Cost, Effectiveness, Side Effects Compared

Cagrilintide at a glance:

• Drug class: Long-acting amylin analog
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Receptor target: amylin receptors (calcitonin receptor + RAMP)

Both options compared on this page are legitimate choices. The differences below are real but mostly modest. The bigger swing factors are usually outside the molecule itself.

Mechanism

Cagrilintide: Cagrilintide is an engineered amylin analog with extended half-life suitable for weekly dosing. Amylin co-released with insulin from beta cells suppresses glucagon, slows gastric emptying, and increases satiety.

semaglutide: Next-generation incretin agonists target combinations of GLP-1, GIP, and glucagon receptors with the goal of greater weight loss and metabolic benefit than GLP-1 alone.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

Cagrilintide: Monotherapy phase 2 showed weight loss of 6-10%; combination with semaglutide pushed total weight loss above 17%.

semaglutide: Most show 15-25% weight loss in late-phase trials.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: Lau et al for Cagrilintide; Per-compound phase 2 or 3 trials for semaglutide.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• nausea
• decreased appetite
• diarrhea
• vomiting

Important risks worth knowing for both:

• limited long-term data
• incomplete long-term safety data pending phase 3 readouts

Cost

Cagrilintide: pricing varies. semaglutide: pricing varies.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for Cagrilintide cost and semaglutide cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between Cagrilintide and semaglutide, either is a defensible choice in most cases.

Switching Between Them

Switching from Cagrilintide to semaglutide (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

If you and your clinician are split between Cagrilintide and a comparator, you're probably in a "no wrong answer" zone. Pick the one with better access for you and reassess in 3 months.

Frequently Asked Questions

Related Reading

• The Honest Guide to Cagrilintide: What Patients and Doctors Actually Say
• Cagrilintide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Cagrilintide Results: Realistic Expectations vs. Trial Headlines
• Why Cagrilintide Costs So Much (and 5 Ways to Pay Less)
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.